Pharmaceutical news: December, 07

“Modern and Traditional Forms of Effective Pharmaceutical Marketing” and Other New Research Reports by PMR Published at

LONDON – Market Publishers Ltd informs that new in-demand market research reports by PMR have been added to its catalogue.

Modern and Traditional Forms of Effective Pharmaceutical Marketing. Based on the Survey of 350 Doctors. The report is based on a survey conducted among 350 medical doctors of seven specializations: paediatrics, general practitioner/family medicine, gynaecology, neurology/ psychiatry, cardiology, pneumology and oncology. The report provides information to pharmaceutical companies on the most effective forms of communication with medical professionals and contains valuable estimations and evaluations of major metrics and issues …

Telecommunications Market in Poland 2010: Development Forecasts for 2010-2014. The report gives a comprehensive overview of the telecommunications market in Poland. It discusses the main events, trends and directions of development in the coming years. In addition to the data for the telecommunications market as a whole, the report analyses all the key segments, namely mobile telephony, fixed-line telephony and ISP. Each chapter offers most recent data on individual segments of the market and presents profiles of the largest players. The report also gives forecasts of the key market indicators and analyses growth opportunities …

Grocery Retail in Central Europe 2010 Poland, Czech Republic, Slovakia, Hungary and Romania: Market Analysis and Development Forecasts for 2010-2012. The global crisis has affected economies within Central Europe differently and on various levels, creating both difficulties and prospects for the businesses. The report presents an accurate, detailed snapshot of the retail food market in Poland, Czech Republic, Slovakia, Hungary and Romania. Along with consumer and retailer profiles, a descriptive statistics concerning the structure and size of the market were analyzed. Macroeconomic overview of the region, market size, composition of the grocery sector and modern shopping centres areas, major distribution channels and profiles of the main market players are reviewed …

More new reports by PMR can be found at

Pfizer’s new boss Ian C Read: the most powerful British executive in the global pharmaceutical industry

However, when Pfizer, the world’s largest pharmaceutical company, promoted Scottish-born Ian C Read to its top job, it’s arguable that Witty lost the distinction. Unlike Witty, who also spent some of his career in the US, Read now has US citizenship.

The move caps a steady but remarkable ascent for Read, who joined Pfizer four years after graduating with a science degree from Imperial College in London in 1974. He also qualified as a chartered accountant. Pfizer’s shareholders, who have had to stomach a 35pc decline in the company’s share price over the past four years, will want to know how Read can blend spreadsheets and science into a brew that puts the share price back on track.

Being described as someone with a long relationship with drugs is not usually a compliment, but the analysts covering Pfizer seized on his experience as a virtue. “I think Ian will be able to talk more deeply and coherently about Pfizer given his many years of experience and his long background in the drug industry,” said Tim Anderson, at Sanford C Bernstein.

Brunei On Track To Have Its First Halal Certified Pharmaceutical Plant

Bandar Seri Begawan – Marking a start of a new chapter in Brunei Darussalam in terms of diversifying the economy, the Minister of Finance II at the Prime Minister’s Office, Pehin Orang Kaya Laila Setia Awang Haji Abdul Rahman bin Haji Ibrahim, yesterday officiated a ground breaking ceremony for the construction of Vivapharm (Brunei), the Sultanate’s first Halal and GMP-certified (Good Manufacturing Practice) manufacturer of pharmaceutical and nutraceutical products in Lambak Kanan (East) Industrial Estate.

In Vivapharm (Brunei), the pharmaceuticals will not only get `CGMP’ licences, as well as certifications from FDA, Health Canada, and NSF, but more importantly, the Brunei Halal Brand. By obtaining this certification, it will help Vivapharm (Brunei) products get into Muslim markets.

Viva Pharmaceutical Inc, Aureos Capital and a group of local investors have committed to invest in Vivapharm (Brunei).

The total investment requirement for Vivapharm (Brunei) will be in the range of B$26 million – out of which Viva Pharmaceutical Inc, Aureos and a group of local investors will commit almost B$15 million.

The remaining funding will be from a local financial institution.

According to Mr Jason Ko, a representative of Kukoh Bersama, it will take between one and oneand-a-half years for construction to be completed. Once it’s ready for operations, Vivapharm Canada will provide formal training programmes, as well as on-the-job training to staff of Vivapharm (Brunei).

Bruneian staff will also have the opportunity to undergo training in Canada.

Through this, Vivapharm hopes to pass on the technical knowledge to Bruneians so as to benefit the Sultanate as a whole.

This venture will also create skilled and semi-skilled jobs in a new industry, in which Brunei aims to become a world leader in manufacturing Halal pharmaceutical products.

Alongside its manufacturing activities, Vivapharm will also invest in Research and Development (R&D), particularly those that are focused on developing new drugs and advanced technologies based on the local flora and fauna found in the “Heart of Borneo”, a mountainous region of almost 85,000 square miles which is covered with equatorial rainforest in the centre of the island

Following the footsteps of Viva Canada, Vivapharm (Brunei) will follow its strategy in investing in R&D.

Vivapharm (Brunei) also intends to work with a local university to provide students the opportunities to pursue a career in the pharmaceutical industry.

Once this project is up and running, Brunei will be the first country to issue guidelines on the production of Halal pharmaceuticals, including the use of alcohols and animal products.

According to Mr Ko, Vivapharm (Brunei) will market Viva’s own brand name products. Vivapharm will focus on the Southeast Asian region, especially in Malaysia and Indonesia.

It also hopes to increase its market share in the Middle East, Asia Pacific, Western Europe and USA.

Mr Ko has high hopes for Vivapharm (Brunei), as the Sultanate will have a “great opportunity” to make this new industry as the “second major industry” after the nation’s oil and gas industry.

This would greatly diversify Brunei’s economy, he added.

Vivapharm, a sub-franchise of Viva Pharmaceuticals Incorporation was established in April 1994 and is now one of the largest GMPcertified pharmaceutical and natural health product manufacturers in British Columbia, Canada.

Viva Pharmaceuticals also obtained GMP & CGMP licences and has NSF certification and Halal certification.

During yesterday’s groundbreaking ceremony, representatives of Brunei Industrial Development Authority (BINA) and Kukoh Bersama signed a lease agreement.

Signing on behalf of BINA was Pengiran Haji Tajuddin bin Pengiran Haji Salleh, while Kukoh Bersama was represented by Pengiran Haji Adanan bin Pengiran Seri Indera Pengiran Haji Ismail.

It was witnessed by Awang Haji Metassan and Mr Ko. — Courtesy of Borneo Bulletin

This entry was posted in News. Bookmark the permalink.

Comments are closed.